- Home
- VLTO vs BNTX Comparison
VLTO vs BNTX Comparison
Compare VLTO & BNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VLTO | BNTX |
|---|---|---|
| Founded | 2023 | 2008 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.5B | 24.8B |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | VLTO | BNTX |
|---|---|---|
| Price | $97.68 | $107.87 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 11 |
| Target Price | $113.25 | ★ $140.31 |
| AVG Volume (30 Days) | ★ 1.4M | 1.1M |
| Earning Date | 02-03-2026 | 03-10-2026 |
| Dividend Yield | ★ 0.51% | N/A |
| EPS Growth | ★ 12.64 | N/A |
| EPS | ★ 3.65 | N/A |
| Revenue | ★ $5,452,000,000.00 | $3,698,814,972.00 |
| Revenue This Year | $8.28 | $2.76 |
| Revenue Next Year | $5.87 | N/A |
| P/E Ratio | $27.80 | ★ N/A |
| Revenue Growth | ★ 6.15 | 3.70 |
| 52 Week Low | $83.87 | $81.20 |
| 52 Week High | $110.11 | $124.49 |
Technical Indicators
Market Signals| Indicator | VLTO | BNTX |
|---|---|---|
| Relative Strength Index (RSI) | 40.62 | 49.75 |
| Support Level | $97.08 | $114.61 |
| Resistance Level | $101.50 | $120.16 |
| Average True Range (ATR) | 1.88 | 3.76 |
| MACD | -0.34 | -0.67 |
| Stochastic Oscillator | 14.36 | 13.65 |
Price Performance
Historical ComparisonAbout VLTO Veralto Corp
Veralto is a diversified industrial firm organized into two segments, water quality as well as product quality and innovation. The water quality segment offers water analytics and water treatment solutions, while the product quality and innovation segment offers coding, packaging, and color solutions for consumer packaged goods and pharmaceuticals. Headquartered in Waltham, Massachusetts, the company has around 17,000 employees. Veralto generated approximately $5.2 billion in revenue in 2024.
About BNTX BioNTech SE
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and antibody-drug conjugates, or ADCs. Comirnaty, its Pfizer-partnered covid vaccine, is its first commercialized product.